



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of) Docket No.: 22338-904/P1101R2D1
Camellia W. ADAMS, et al.)
Application No.: 10/052,798) Examiner: Eileen B. O'Hara
Filed: November 2, 2001) Group Art Unit: 1646
For: APO-2 RECEPTOR)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, 1.97 and 1.98,
Applicant cites the documents listed on the Form PTO-SB/08a that accompanies this paper.
Applicant does not represent that a search has been conducted or that the cited documents are
prior art against the claims in this application.

Applicant also directs the examiner's attention to the commonly owned U.S. applications
listed below, which may disclose subject matter related to the instant application. The examiner
is invited to review the file wrappers of the following applications which may be relevant to the
prosecution of the instant case.

Serial No.	Filing Date	First Inventor	Status
09/096,637	June 12, 1998	Avi J. ASHKENAZI	Abandoned
09/396,710	Sept 15, 1999	Avi J. ASHKENAZI	Abandoned
10/207,295	July 29, 2002	Avi J. ASHKENAZI	Abandoned
08/857,216	May 15, 1997	Avi J. ASHKENAZI	Pending
09/020,746	February 9, 1998	Avi J. ASHKENAZI	Abandoned

10052798

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Application No. 10/052,798

Docket No. 22338-904

11/402,914	April 13, 2006	Avi J. ASHKENAZI	Pending
60/074,119	February 9, 1998	Camellia W. ADAMS	Abandoned
60/046,615	May 15, 1997	Camellia W. ADAMS	Abandoned
09/079,029	May 14, 1998	Camellia W. ADAMS	Issued
10/288,917	November 6, 2002	Camellia W. ADAMS	Abandoned
10/423,448	April 25, 2003	Camellia W. ADAMS	Interference
10/627,429	July 25, 2003	Camellia W. ADAMS	Abandoned
11/245,053	October 7, 2005	Camellia W. ADAMS	Pending
11/297,319	December 9, 2005	Camellia W. ADAMS	Pending
11/297,326	December 9, 2005	Camellia W. ADAMS	Pending
11/297,327	December 9, 2005	Camellia W. ADAMS	Pending
11/297,448	December 9, 2005	Camellia W. ADAMS	Pending
11/483,978	July 11, 2006	Camellia W. ADAMS	Pending

In addition to those patent applications, Applicant also wishes to bring to the attention of the examiner Interference proceeding Nos. 105,361, 105,240, 105,380 and 105,381 which may pertain to related subject matter. U.S. application serial no. 10/423,448 involved in Interference No. 105,361 makes a claim under 35 U.S.C. § 120 to the present application. For the convenience of the examiner, Applicant has provided a copy of the motion lists filed by each party in Interference No. 105,361 in conjunction with the accompanying Form PTO SB/08. Also, Applicants have sought to list on the accompanying Form PTO SB/08 and provide copies, as necessary, of the patent, patent application and journal reference exhibits relied upon by the parties in Interference No. 105,361 that have not already been made of record.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-SB/08a, and to indicate in the official file wrapper of this patent application that the documents have been considered.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Application No. 10/052,798

Docket No. 22338-904

The present Information Disclosure Statement is being filed prior to the mailing of a final office action and is accompanied by the fee under 37 C.F.R. § 1.17(p).

Copies of the references listed on the attached Form PTO- SB/08a which were previously cited in Serial Number 09/079,029 filed May 14, 1998 and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120 have not been provided pursuant to 37 CFR § 1.98(d). However, if the examiner is unable to obtain copies of any of the listed references, Applicant will do its best to supply those references in a timely fashion.

The Director is directed and authorized to charge the fee under 37 C.F.R. § 1.17(p) and any credits and any overpayments to Deposit Account No. 18-1260.

Respectfully submitted,



Jeffrey P. Kushan

Registration No. 43,401

Attorney for the Applicant

Date: 11/3/06

Sidley Austin LLP

1501 K Street, N.W.

Washington, D.C. 20005

Telephone Number: (202) 736-8000

891425v1<DC1>



**INFORMATION
DISCLOSURE
STATEMENT**

Docket No. 22338-904/P1101R2D1

Application No.
10/052,798

Applicant(s): Camellia W. ADAMS, et al.

Examiner: O'Hara,
Eileen

Filing Date: November 2, 2001

Group Art Unit: 1646

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date (If Appropriate)
		08/857,216		Ashkenazi, Avi			05-15-1997
		09/020,746		Ashkenazi, Avi			01-16-1996
		09/042,583		Jian Ni et al.			03-17-1998
		09/079,029		Adams et al.			05-14-1998
		09/096,637		Ashkenazi, Avi			06-12-1998
		09/396,710		Avi Ashkenazi			9-15-1999
		09/828,739		Ashkenazi, Avi			04-09-2001
		10/005,842		Jian Ni et al.			12-07-2001
		10/052,798		Adams, Camellia			11-02-2001
		10/288,917		Adams, Camellia			11-06-2002
		10/423,448		Adams, Camellia			04-25-2003
		10/627,429		Adams, Camellia			07-25-2003
		10/648,825		Jian Ni et al.			08-27-2003
		11/297,319		Adams, Camellia			12-09-2005
		11/297,326		Adams, Camellia			12-09-2005
		11/455,062		Ashkenazi, Avi			06-16-2006
		11/483,978		Adams, Camellia			07-11-2006
		2002-0150985 A1 (10/052,798)	10-17-2002	Adams, Camellia			
		2003/0004313		Ashkenazi, Avi			
		2003-0017161 A1 (10/207,295)	01-23-2003	Ashkenazi, Avi			
		2003-0148455 A1 (10/288,917)	08-07-2003	Ashkenazi, Avi			
		2004-0009552 A1 (10/423,448)	01-15-2004	Adams, Camellia			
		US 2005-0233958 A1 (10/979,831)	10-20-2005	Jian Ni			
		US 2005-0282230 A1 (11/104,779)	12-22-2005	Ashkenazi, Avi			
		US-2006-0035334 A1 (11/245,053)	02-16-2006	Adams, Camellia			
		US-2006-0073570 A1 (11/297,327)	04-06-2006	Adams, Camellia			
		US-2006-0084147 A1 (11/297,448)	04-20-2006	Adams, Camellia			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-SB/08 (modified)

SHEET 1 OF 8

INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-904/P1101R2D1	Application No. 10/052,798
	Applicant(s): Camellia W. ADAMS, et al.	Examiner: O'Hara, Eileen
	Filing Date: November 2, 2001	Group Art Unit: 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Alderson et al., "Fas Transduces Activation Signals in Normal T lymphocytes", J. Exp. Med., 178:2231-2235 (1993)
	Alderson et al., "Regulation of apoptosis and T cell activation by Fax-specific mAb" International Immunology, 6(11): 1799-1806 (1994)
	Altschul et al., "Basic Local Alignment Search Tool" J. Mol. Biol. 215, 403-410 (1990)
	Armitage et al., Nature 357:80 (1992)
	Basic Pharmacology 4 th Edition, Chapter 1: General Pharmacology p. 1-32 (1996)
	Beg, et al., "An Essential Role for NF-kB in Preventing TNF-a-Induced Cell Death, Science 274:782-784 (1996)
	Bennett et al., J. Biol. Chem. 269(19): 14211 (1994)
	Brutlag et al., "Improved sensitivity of biological sequence database searches" CABIOS Vol. 6 no. 3. Pages 237-245 (1990)
	Carter et al., Neuron 18: 187-190 (1997)
	Casaccia-Bonnet et al., Nature 383: 716 (1996)
	Chaudhary et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF-153B Pathway" Immunity 7:821-830 (1997)
	Chu, G., "Cellular Responses to Cisplatin, J. Bio. Chem. 269:2, 787-790 (1994)
	Chuntharapai and Kim, "Generation of Monoclonal Antibodies to Chemokine Receptors," Methods in Enzymology 288:15-27 (1997)
	Chuntharapai et al., J. Immunol. 166:4891 (2001)
	Cifone, et al., "Apoptotic Signaling through CD95 (Fas/Apo-1) Activates an Acidic Sphingomyelinase" J. Exp. Med., 177:1547-1552 (1993)
	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" Cell 81:479-482 (1995)
	Clewley and Arnold, "MEGALIGN: The Multiple Alignment Module of LASERGENE" From: Methods in Molecular Biology, Vol. 70: Sequence Data Analysis Guidebook, pp. 119-129 (1997)
	Curtiss and Witzum, "A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins", J. Clin. Invest. 72(4):1427-1438 (1983)
	De Benedette, et al., "Role of 4-1BB ligand in costimulation", J. Exp. Med., 181:985 (1995)
	Devereux et al., "A comprehensive set of sequence analysis programs for the VAX" Nucleic Acids Research Vol. 12 No. 1:387-395 (1984)
	Doctor et al., Cell Death and Differentiation 10:621-633 (2003)
	Edelman, Gerald, M. "Antibody Structure and Molecular Immunology," Nobel Lecture, December 12, 1972
	Eischen, et al., "Comparison of Apoptosis in Wild-Type and Fas-resistance Cells: Chemotherapy-Induced Apoptosis is Not Dependant on Fas/Fas Ligand Interactions, Blood 90:935-943 (August 1997)
	Emery et al., "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL" J. Biol. Chem. 273:14363-14367 (1998)
	Enari et al., "Involvement of an ICE-like protease in Fas-mediated Apoptosis" Nature 375:78-81 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-SB/08 (modified)

SHEET 4 OF 8

INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-904/P1101R2D1	Application No. 10/052,798
	Applicant(s): Camellia W. ADAMS, et al.	Examiner: O'Hara, Eileen
	Filing Date: November 2, 2001	Group Art Unit: 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Engelmann et al., "Antibodies to a Soluble Form of a Tumor Necrosis Factor (TNF) Receptor Have TNF-like Activity" J. of Biol. Chem. 265(24):14497-14504 (1990)
	Espevik et al., "Characterization of Binding and Biological Effects of Monoclonal Antibodies against a Human Tumor Necrosis Factor Receptor" J. Exp. Med. 171:415-426 (1990)
	Essentials of Pharmacology 2 nd Edition, Chapter 1: General Principles and Pharmacokinetics p. 1-33 (1996)
	Fadeel et al., "Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects <i>in vitro</i> " International Immunology, 9(2):201-209 (1996)
	Feinstein, E., et al. "The Death Domain: A Module Shared by Proteins with Diverse Cellular Functions, TIBS 20:342-344 (1995)
	Feldman et al. "TNF α as a Therapeutic Target in Rheumatoid Arthritis" Circulatory Shock 43:179-184 (1994)
	Frade et al., Nature 383:166 (1996)
	Goding, "Production of Monoclonal Antibodies" Monoclonal Antibodies: Principles and Practice, Academic Press, pps. 59
	Greenaway et al., "Human Cytomegalovirus DNA: BamHI, EcoRI and PstI Restriction Endonuclease Cleavage Maps" Gene 18:355
	Griffiths, et al. "Human anti-self antibodies with high specificity from phage display libraries", The EMBO J., 12:725-734 (1993)
	Hess, S., "A Novel Function of CD 40: Induction of Cell Death in Transformed Cells, J. Exp. Med. 183:159-167 (1996)
	Higgins and Sharp, "CLUSTAL: a package for performing multiple sequence alignment on a microcomputer" Gene. 73(1) 237-244 (1988)
	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF141\ nor)" Journal of Biological Chemistry 264(25):14927-14934 (1989)
	Hsu, H., "The TNF Receptor-1 Associated Protein TRADD Signals Cell Death and NF-kB Activation, Cell, 81:495-504 (1995)
	Huisman et al., "Paclitaxel Triggers Cell Death Primarily via Caspase-independent Routes in the Non-Small Cell Lung Cancer Cell Line NCI-H460," Clinical Cancer Research 8:596-606 (2002)
	Itoh and Nagata, "A Novel Protein Domain Required for Apoptosis (Mutational Analysis of Human Fas Antigen" Journal of Biological Chemistry, Vol. 268, No. 15, May 25, pp. 10932-10937 (1993)
	James, K., "Human Monoclonal Antibody Technology," The Pharmacology of Monoclonal Antibodies: Handbook of Experimental Pharmacology, Rosenberg and Moore, eds., Berlin:Springer-Verlag, Chapter 1, Vol. 113:3-22 (1994)
	Johnson et al., "Signal Transduction Pathways Regulated by Mitogen-activated/Extracellular Respnse Kinase Kinase Kinase Induce Cell Death" J. Biol. Chem. 271:3229-3237 (1996)
	Kabat et al., "Attempts to locate residues in complementarity-determining regions of antibody combining sites that make contact with antigen, Proc. Nat. Acad. Sci., 73:617-619 (1976)
	Kabat et al., Some correlations between specificity and sequence of the first complementarity-determining region segments of human Kappa light chains, PNAS 73: 4471-4473
	Kehoe & Seide, "Immunoglobulin structure and function: genetic control of antibody diversity, J. Am. Vet. Med. Assoc. 181(10):1000-1004, (1982)
	Kobayashi et al., "Specificity problem of polyclonal rabbit antibody" J. Clin. Pathol. 41:705-706, 1988

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-SB/08 (modified)

SHEET 5 OF 8

INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-904/P1101R2D1	Application No. 10/052,798
	Applicant(s): Camellia W. ADAMS, et al.	Examiner: O'Hara, Eileen
	Filing Date: November 2, 2001	Group Art Unit: 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Lippincott's Illustrated Reviews: Pharmacology 2 nd Edition, Chapter 2: Pharmacokinetics and Drug Receptors p. 17-26 (1997)
	Liu, et al., "Mechanism of antigen-driven selection in germinal centres, Nature, 342:929-931 (1989)
	Locksley et al., "The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology" Cell 104:487-501 (February 2001)
	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" Journal of Biological Chemistry 272(41):25417-25420 (1997)
	MacKay et al., "Differential Responses of Fibroblasts from Wild-Type and TNF-R55-Deficient Mice to Mouse and Human TNF- α Activation" J. Immunol. 153:5274-5284 (1994)
	Maini et al., "Targeting TNF α for the therapy of rheumatoid arthritis" Clinical and Experimental Rheumatology 12 (Suppl. 11): 563-566 (1994)
	Mapara, et al., "APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression, Eur. J. Immunol. 23:702-708
	Mark et al., J. Biol. Chem. 269(14): 10720 (1994)
	Morrison, et al., "Analysis of receptor clustering on cell surfaces by imaging fluorescent particles, Biophys. J., 67(3):1280-1290 (1994)
	Mühlenbeck et al., J. Biol. Chem. 275(41): 32208 (2000)
	Naismith & Sprang, "Tumor Necrosis Factor Receptor Superfamily," J. Inflamm., 47:1-7 (1996)
	Nakai and Kanehisa, "A Knowledge Base for Predicting Protein Localization Sites in Eukaryotic Cells" Genomics 14:897-911 (1992)
	Novotny et al., "Molecular Anatomy of the Antibody Binding Site, J. Biol. Chem., 258:14433-14437 (1983)
	Ogasawara et al., Nature 364:806 (1993)
	Prakash, V., et al. "The Interaction of Vincristine with Calf Brain Tubulin, J. Bio. Chem., 258:3, 1689-1697 (1983)
	Reed, Amer. J. Path. 157(5):1415-1430 (2000)
	Reed et al., Sci. STKE 2004, re9 (2004)
	Rennert, et al., "Surface Lymphotoxin α /B complex is required for development of peripheral lymphoid organs," J. Exp. Med., 184:1999 (1996)
	Ross, Elliott M., "Pharmacodynamics: Mechanisms of Drug Action and the Relationship Between Drug Concentration and Effect" Goodman & Gilman's The Pharmacological Basis Of Therapeutics, Ninth Edition, Chapter 2: pp. 29-41 (1996)
	Sato, et al., "A novel member of the TRAF family of putative signal transducing protein binds to the cytosolic domain of CD40, FEBS Letters 358:113-118 (1995)
	Sevier, et al., "Monoclonal Antibodies in Clinical Immunology, Clin. Chem., 27:1797-1806 (1981)
	Sheehan et al., "Monoclonal Antibodies Specific for Murine p55 and p75 Tumor Necrosis Factor Receptors: Identification of a Novel In Vivo Role for p75" J. Exp. Med. 181:607-617 (1995)
	Srivastava, "TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer," Neoplasia 3:535-546 (2001)
	Stedman's Medical Dictionary, 26 th Edition, p. 38 (1995)
	Tartaglia et al., "The two different receptors for tumor necrosis factor mediate distinct cellular responses" Proc. Natl. Acad. Sci. USA 88:9292-9296 (October 1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-SB/08 (modified)

SHEET 6 OF 8

